Related Experiment Videos
Gene therapy for cystic fibrosis
1University of Florida Genetics Institute, JHMHSC, Gainesville 32610-0266, USA. flottr@peds.ufl.edu
Current Opinion in Molecular Therapeutics
|November 21, 2001
Summary
Developing effective gene therapy for cystic fibrosis (CF) faces challenges in airway gene transfer due to host defenses and vector limitations. Ongoing trials aim to overcome these obstacles for successful CF genetic treatments.
Area of Science:
- Medical research
- Genetics
- Pulmonology
Background:
- Cystic Fibrosis (CF) is a genetic disorder affecting the lungs.
- Gene therapy aims to correct the underlying genetic defect in CF.
- Effective gene transfer to CF airways remains a significant challenge.
Purpose of the Study:
- To review the current state of gene therapy for cystic fibrosis.
- To discuss the obstacles hindering effective gene transfer in CF airways.
- To analyze the characteristics of available gene transfer vector systems.
Main Methods:
- Literature review of gene therapy approaches for CF.
- Analysis of airway biology and CF pathophysiology.
- Evaluation of viral and non-viral gene transfer vectors.
Main Results:
- Significant advances have been made in vector development.
- Host defense mechanisms and vector properties impede clinical gene transfer.
- Human trials are crucial for identifying and addressing these obstacles.
Conclusions:
- Overcoming host defense and vector limitations is key to successful CF gene therapy.
- A comprehensive understanding of airway biology and pathophysiology is essential.
- Continued research and clinical trials are necessary to advance CF gene therapy.